Zengbin Wang

7PUBLICATIONS
7CO-AUTHORS
Molecular targetsHaematological tumoursPredictive and prognostic markersInnate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Sep 17, 2026
Doxorubicin-induced hepatotoxicity: a multifaceted pathogenesis from mitochondrial collapse to immune remodeling and epigenetic memory.

|May 29, 2026
Ripk2 promotes CD8+ T cell inactivation and hepatocellular carcinoma progression through Myb/Cxcl9 and Pax5/Adpgk signaling pathways.

|Apr 15, 2026
Non-enzymatic Rnaseh2c orchestrates proliferating macrophage-driven immunosuppression and HCC progression via Cdk9 proliferation axis and CCL2/CCR2-mediated CD8+ Tex infiltration: a novel therapeutic paradigm with "Rnaseh2c-In1" inhibitor.

|Dec 08, 2025
RNASEH2C enhances TRAF3IP1 to degrade RAI14 in lysosomes thus hindering macrophage antigen presentation and advancing liver cancer.

Banglun Pan, Huahui Yu, Zikun Lin

|Nov 17, 2025
Lactylated SPTAN1 Accelerates Hepatocellular Carcinoma Progression by Promoting NOTCH1/HES1 Activation and Immunosuppression.

Zengbin Wang, Dongjie Ye, Linqing Wu

|Jul 23, 2025
RBM17 promotes hepatocellular carcinoma progression by regulating lipid metabolism and immune microenvironment: implications for therapeutic targeting.

Zengbin Wang, Jiayu Liu, Yiting Lai

Pageof 2

Frequent Collaborators

3 joint publications

Nanhong Tang

3 joint publications

Zhuting Fang

1 joint publications

Banglun Pan

1 joint publications

Linqing Wu